Free Trial

Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consistently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

iBio stock logo

1. iBio NASDAQ:IBIO

$0.72 -0.04 (-5.41%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBio

Market Capitalization
$46.30 million
Consensus Rating
Buy
Consensus Price Target
$6.00 (+732.2% Upside)
Volume
175,768 shares
Average Volume
1.06 million shares
Today's Range
$0.72
▼
$0.80
Ur Energy stock logo

2. Ur Energy NYSEAMERICAN:URG

$0.61 -0.01 (-2.02%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur Energy

Market Capitalization
$241.24 million
Consensus Rating
Buy
Consensus Price Target
$2.11 (+247.9% Upside)
Volume
1.25 million shares
Average Volume
9.63 million shares
Today's Range
$0.60
▼
$0.64
Tenaya Therapeutics stock logo

3. Tenaya Therapeutics NASDAQ:TNYA

$0.34 -0.01 (-3.31%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya Therapeutics

Market Capitalization
$76.58 million
Consensus Rating
Moderate Buy
Consensus Price Target
$4.00 (+1,090.5% Upside)
Volume
346,523 shares
Average Volume
3.43 million shares
Today's Range
$0.34
▼
$0.35
Perspective Therapeutics stock logo

4. Perspective Therapeutics NYSEAMERICAN:CATX

$0.88 +0.04 (+5.06%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More about Perspective Therapeutics

Market Capitalization
$106.87 million
Consensus Rating
Moderate Buy
Consensus Price Target
$10.10 (+1,041.2% Upside)
Volume
493,739 shares
Average Volume
2.40 million shares
Today's Range
$0.85
▼
$0.93
Allogene Therapeutics stock logo

5. Allogene Therapeutics NASDAQ:ALLO

$0.83 0.00 (-0.12%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. More about Allogene Therapeutics

Market Capitalization
$287.92 million
Consensus Rating
Moderate Buy
Consensus Price Target
$8.30 (+904.8% Upside)
Volume
1.65 million shares
Average Volume
7.93 million shares
Today's Range
$0.84
▼
$0.85
Connect Biopharma stock logo

6. Connect Biopharma NASDAQ:CNTB

$0.65 -0.02 (-2.60%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. More about Connect Biopharma

Market Capitalization
$40.81 million
Consensus Rating
Moderate Buy
Consensus Price Target
$5.88 (+806.6% Upside)
Volume
29,754 shares
Average Volume
1.36 million shares
Today's Range
$0.65
▼
$0.70
Neumora Therapeutics stock logo

7. Neumora Therapeutics NASDAQ:NMRA

$0.43 0.00 (-0.92%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. More about Neumora Therapeutics

Market Capitalization
$80.61 million
Consensus Rating
Moderate Buy
Consensus Price Target
$6.57 (+1,431.8% Upside)
Volume
43,726 shares
Average Volume
1.72 million shares
Today's Range
$0.42
▼
$0.49
Compass Therapeutics stock logo

8. Compass Therapeutics NASDAQ:CMPX

$0.76 -0.06 (-7.20%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass Therapeutics

Market Capitalization
$136.33 million
Consensus Rating
Moderate Buy
Consensus Price Target
$9.99 (+1,213.0% Upside)
Volume
192,199 shares
Average Volume
4.47 million shares
Today's Range
$0.78
▼
$0.83
Nouveau Monde Graphite stock logo

9. Nouveau Monde Graphite NYSE:NMG

$0.77 -0.01 (-0.87%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Nouveau Monde Graphite Inc engages in the acquisition, exploration, development, and evaluation of mineral properties in Quebec, Canada. More about Nouveau Monde Graphite

Market Capitalization
$252.14 million
Consensus Rating
Moderate Buy
Consensus Price Target
$3.87 (+405.2% Upside)
Volume
16,606 shares
Average Volume
787,431 shares
Today's Range
$0.76
▼
$0.79
Milestone Pharmaceuticals stock logo

10. Milestone Pharmaceuticals NASDAQ:MIST

$0.57 -0.08 (-12.24%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. More about Milestone Pharmaceuticals

Market Capitalization
$71.59 million
Consensus Rating
Moderate Buy
Consensus Price Target
$6.40 (+1,013.0% Upside)
Volume
991,704 shares
Average Volume
1.73 million shares
Today's Range
$0.55
▼
$0.70
Biomea Fusion stock logo

11. Biomea Fusion NASDAQ:BMEA

$0.55 -0.02 (-2.97%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea Fusion

Market Capitalization
$39.76 million
Consensus Rating
Moderate Buy
Consensus Price Target
$7.60 (+1,291.9% Upside)
Volume
89,734 shares
Average Volume
1.48 million shares
Today's Range
$0.55
▼
$0.59
Bit Digital stock logo

12. Bit Digital NASDAQ:BTBT

$0.69 -0.08 (-10.49%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Bit Digital, Inc, together with its subsidiaries, engages in the bitcoin mining business. It is also involved in the treasury management activities; and digital asset staking and digital asset mining businesses, as well as ethereum staking activities. More about Bit Digital

Market Capitalization
$246.31 million
Consensus Rating
Moderate Buy
Consensus Price Target
$4.25 (+519.5% Upside)
Volume
2.45 million shares
Average Volume
25.68 million shares
Today's Range
$0.69
▼
$0.77
enCore Energy stock logo

13. enCore Energy NASDAQ:EU

$0.53 -0.01 (-1.11%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

enCore Energy Corp. engages in the acquisition, exploration, and development of uranium resource properties in the United States. More about enCore Energy

Market Capitalization
$104.29 million
Consensus Rating
Moderate Buy
Consensus Price Target
$2.23 (+318.4% Upside)
Volume
654,139 shares
Average Volume
3.63 million shares
Today's Range
$0.53
▼
$0.58
Hyperfine stock logo

14. Hyperfine NASDAQ:HYPR

$0.65 -0.03 (-4.46%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Hyperfine, Inc, a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. More about Hyperfine

Market Capitalization
$68.83 million
Consensus Rating
Moderate Buy
Consensus Price Target
$2.03 (+212.0% Upside)
Volume
139,128 shares
Average Volume
724,277 shares
Today's Range
$0.65
▼
$0.68
Humacyte stock logo

15. Humacyte NASDAQ:HUMA

$0.57 -0.03 (-4.94%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. More about Humacyte

Market Capitalization
$157.24 million
Consensus Rating
Moderate Buy
Consensus Price Target
$4.48 (+691.7% Upside)
Volume
530,286 shares
Average Volume
7.54 million shares
Today's Range
$0.58
▼
$0.61
Canaan stock logo

16. Canaan NASDAQ:CAN

$0.15 -0.01 (-4.53%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Canaan Inc engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. More about Canaan

Market Capitalization
$110.30 million
Consensus Rating
Moderate Buy
Consensus Price Target
$1.35 (+776.6% Upside)
Volume
2.36 million shares
Average Volume
12.74 million shares
Today's Range
$0.16
▼
$0.16
ALX Oncology stock logo

17. ALX Oncology NASDAQ:ALXO

$0.95 -0.13 (-12.13%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. More about ALX Oncology

Market Capitalization
$131.23 million
Consensus Rating
Moderate Buy
Consensus Price Target
$4.75 (+400.5% Upside)
Volume
122,553 shares
Average Volume
1.08 million shares
Today's Range
$1.00
▼
$1.12
BitFuFu stock logo

18. BitFuFu NASDAQ:FUFU

$0.89 -0.02 (-1.97%)
As of 10:22 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BitFuFu Inc provides digital asset mining and cloud-mining services in Singapore. It also offers miner rental, and miner hosting and sales services to institutional customers and individual digital asset enthusiasts. More about BitFuFu

Market Capitalization
$148.45 million
Consensus Rating
Moderate Buy
Consensus Price Target
$5.00 (+461.2% Upside)
Volume
3,437 shares
Average Volume
416,761 shares
Today's Range
$0.89
▼
$0.93
DeFi Technologies stock logo

19. DeFi Technologies NASDAQ:DEFT

$0.33 +0.03 (+9.35%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

DeFi Technologies, Inc engages in the provision of investment services. It plans to acquire equity, debt, or other securities of publicly traded or private companies or other entities. More about DeFi Technologies

Market Capitalization
$128.93 million
P/E Ratio
5.53
Consensus Rating
Moderate Buy
Consensus Price Target
$1.44 (+333.0% Upside)
Volume
1.17 million shares
Average Volume
3.93 million shares
MindWalk stock logo

20. MindWalk NASDAQ:HYFT

$1.00 -0.01 (-0.50%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. More about MindWalk

Market Capitalization
$47.34 million
Consensus Rating
Moderate Buy
Consensus Price Target
$5.00 (+402.5% Upside)
Volume
63,178 shares
Average Volume
345,989 shares
Today's Range
$0.98
▼
$1.00
Lucid Diagnostics stock logo

21. Lucid Diagnostics NASDAQ:LUCD

$0.46 +0.04 (+10.74%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid Diagnostics

Market Capitalization
$93.69 million
Consensus Rating
Moderate Buy
Consensus Price Target
$4.19 (+808.4% Upside)
Volume
1.29 million shares
Average Volume
2.36 million shares
Today's Range
$0.42
▼
$0.48
Ocugen stock logo

22. Ocugen NASDAQ:OCGN

$0.85 -0.02 (-2.70%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. More about Ocugen

Market Capitalization
$288.41 million
Consensus Rating
Moderate Buy
Consensus Price Target
$9.50 (+1,017.6% Upside)
Volume
1.83 million shares
Average Volume
7.15 million shares
Today's Range
$0.85
▼
$0.89
Rani Therapeutics stock logo

23. Rani Therapeutics NASDAQ:RANI

$0.51 -0.01 (-2.51%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani Therapeutics

Market Capitalization
$71.37 million
Consensus Rating
Moderate Buy
Consensus Price Target
$8.33 (+1,527.6% Upside)
Volume
56,518 shares
Average Volume
881,017 shares
Today's Range
$0.51
▼
$0.53
HeartBeam stock logo

24. HeartBeam NASDAQ:BEAT

$0.38 -0.02 (-5.87%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. More about HeartBeam

Market Capitalization
$21.47 million
Consensus Rating
Moderate Buy
Consensus Price Target
$4.00 (+952.6% Upside)
Volume
166,527 shares
Average Volume
2.96 million shares
Today's Range
$0.38
▼
$0.40
Context Therapeutics stock logo

25. Context Therapeutics NASDAQ:CNTX

$0.18 -0.01 (-6.57%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context Therapeutics

Market Capitalization
$16.91 million
Consensus Rating
Moderate Buy
Consensus Price Target
$6.40 (+3,359.5% Upside)
Volume
79,550 shares
Average Volume
1.72 million shares
Today's Range
$0.19
▼
$0.21